tions' requirements for safety management and documentation of processes to reduce the risks of endemic and epidemic nosocomial infections. ( 
To the Editor:
The study by Coronado et al 1 provided important information about the epidemiology of ciprofloxacin resistance in Staphylococcus aureus and Pseudomonas aeruginosa. In the discussion section of the paper, the authors cited our paper that reported results of epidemiological typing of S aureus by DNA restriction fragment-length polymorphisms of rRNA genes (ribotyping). 2 Coronado et al have misquoted results from our study and have attributed results from typing studies of methicillin-susceptible S aureus (MSSA) to methicillin-resistant S aureus (MRSA). Our report indicated that ribotyping demonstrated that a number of different strains or clones of MRSA existed at the Atlanta VA Medical Center and that ciprofloxacin resistance had emerged in multiple strains of MRSA as opposed to primarily a single strain or clone of MSSA. Selective pressure appeared to play an important role in the development of ciprofloxacin resistance in MRSA, as resistance was not documented until after the drug was introduced into the hospital formular y in late May 1988 and increased rapidly from 0% to approximately 80% in a 1-year period. 3 Currently, 89% of MRSA isolates and 8% of MSSA isolates recovered from the Atlanta VA Medical Center are resistant to ciprofloxacin.
